Ophthalmic Disease Models

In recent years, significant progress has been made in understanding the genetic factors underlying various ophthalmic diseases. The development of relevant animal models has played a crucial role in advancing preclinical research, including the study of disease mechanisms, drug target identification, and evaluation of treatment efficacy.


Cyagen has created a series of gene-edited models for ophthalmic diseases, such as Leber Congenital Amaurosis 2 (LCA2), Leber Congenital Amaurosis 10 (LCA10), retinitis pigmentosa, retinal degeneration, age-related macular degeneration, and corneal endothelial dysfunction. These models exhibit well-defined phenotypic characteristics and offer stable and heritable genetic traits, making them valuable tools for various ophthalmology-related investigations.


Additionally, Cyagen provides a specialized platform for ophthalmic pharmacology analysis. This comprehensive service covers ocular drug administration, in vivo ocular detection, ocular tissue collection, histological analysis, and gene and protein expression detection, ensuring integrate evaluation of ophthalmic drug efficacy.



Validated Ophthalmic Disease Models

Product ID Product Name Related Diseases Targeting Type
C001395 hVEGFA-TG Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR) Humanization(TG)
C001396 B6-hRho Retinitis Pigmentosa (RP) Humanization(KI)
C001384 Pde6b KO Retinitis Pigmentosa (RP), Congenital Stationary Night Blindness (CSNB) KO
C001385 Prph2 KO Retinitis Pigmentosa (RP), Age-related Macular Degeneration (AMD), Macular Dystrophy (MDs) KO
C001386 Tub-KO Retinal Degeneration (RD) KO
C001387 Rpe65 KO Retinal Degeneration (RD), Leber Congenital Amaurosis 2 (LCA2) KO
C001360 B6-Rpe65 R44X Leber Congenital Amaurosis 2 (LCA2) Mu
C001425 Nr2e3 KO Enhanced S Cone syndrome, ESCS; Retinitis pigmentosa, RP KO



Other Ophthalmic Disease Models

Related Diseases Target Gene Targeting Type
Macular degeneration Vegfa Humanization(KI)
Abca4(Abcr) KO, CKO, Humanization
Retinitis pigmentosa, RP Rho KO, CKO, Humanization(WT, MU)
Mertk KO, CKO
Rpgr KO, CKO
Crb1 KO, CKO
Rd1(Pde6b) MU
Rd10(Pde6b) MU
Retinal Degeneration Slow, RDS Prph2 KO, CKO
Leber's congenital amaurosis 4, LCA4 Aipl1 KO, CKO
Leber's congenital amaurosis 10, LCA10 Cep290 KO, CKO, Humanization(WT, MU)
Leber's congenital amaurosis 13, LCA13 Rdh12 KO, CKO
Achromatopsia, ACHM Cnga3 KO, CKO
Dystrophia endothelialis corneae Tcf4 KO, CKO, Humanization
Congenital aniridia Pax6 KO, CKO
Choroideremia, CHM Chm KO, CKO
Usher syndrome, USH Ush2A Humanization(WT, MU)
Vitelliform macular degeneration, VMD Best1 KO, CKO
X-linked retinoschisis, RS Rs1 KO, CKO
Oculocutaneous albinism type, OCA1 Tyr CKO
Oculocutaneous albinism type 3, OCA3 Tyrp1 KO, CKO
Ocular albinism, OA Gpr143 KO, CKO
Bietti crystalline comeoretinal dystrophy, BCD Cyp4v3 KO, CKO
Corneal dystrophy, CD Tgfbi KO, CKO, MU, Humanization
Wolfram syndrome Wfs1 KO, CKO
Pseudoxanthoma Elasticum, PXE Abcc6 KO, CKO
Retinitis pigmentosa, RP/Leber's congenital amaurosis, LCA Tub CKO
Enhanced S Cone syndrome, ESCS Nr2e3 KO, CKO